Please login to the form below

Immuno-oncology: The market opportunity for PD-1/PD-L1s


Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.

http://www.researchpartnership.com/news/2016/08/infographic-immunno-oncology/

23rd November 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan
Research Partnership
Research Partnership’s MedTech Division appoints two Directors
Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.
Research Partnership
Webcast: Influencing HCP behaviours – Is now the perfect opportunity?
Putting behavioural science at the forefront of market research
Research Partnership
Quantitative specialist joins Research Partnership, London
Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London
Research Partnership
Webcast
Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights
Research Partnership
Webcast
The power of a good story: Turn your insights into effective storytelling with data visualisation
Research Partnership